Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies

X
Trial Profile

A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs P 006 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Fallopian tube cancer; Merkel cell carcinoma; Neuroendocrine carcinoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors 23andMe
  • Most Recent Events

    • 04 Jun 2024 Results (Between March 27 and October 23, 2023, n=15) reporting data from the ovarian cancer Phase 2a expansion cohort , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Results (n=16) assessing safety and efficacy of 23ME-00610 in patients with advanced neuroendocrine cancers presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2024 According to a 23andMe Holding media release, 16 adult patients with advanced neuroendocrine neoplasms and 16 adult patients with advanced ovarian cancer have been enrolled in this trial
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top